• CPHInorth America
• 22 Mar, 2019

Efforts to ease the patient burden with multi-API products and the increasing number of candidate products with low bioavailability are creating opportunities for contract\manufacturing and development organizations (CDMOs) to create value with innovative, but complex finished dosage formulations. Providing patients with solutions that allow them to dose less frequently and reduce complexity are a major selling point, CDMOs says.
Read more...